Clinical Trials Browser

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT01658241 2022-05-06

VEG VCA1

Phase 2 Completed

30 enrolled

Plasma cell

Multiple Myeloma

NCT00550277 2021-11-23

LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

Phase 2 Completed

20 enrolled 7 charts

Genitourinary

Carcinoma, Renal Cell

NCT00425555 2021-08-20

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

Phase 2 Completed

139 enrolled 21 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00742027 2021-07-28

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Phase 2 Completed

129 enrolled 16 charts

Lymphoid

Hodgkin Disease

NCT00667862 2021-06-21

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

Phase 2 Completed

35 enrolled 8 charts

Genitourinary

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00936611 2021-01-28

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

Phase 2 Completed

39 enrolled 13 charts

Lymphoid

Waldenstrom Macroglobulinemia, Recurrence

NCT01802879 2019-12-06

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

Phase 2 Completed

9 enrolled 8 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT01013597 2019-11-29

Trial of LBH589 in Metastatic Thyroid Cancer

Phase 2 Completed

13 enrolled 11 charts

Head & Neck

Thyroid Diseases, Thyroid Neoplasms

NCT01523834 2019-11-22

FIL_PanAL10

Phase 2 Completed

35 enrolled 10 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02290431 2019-11-18

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Completed

31 enrolled 19 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT01651039 2018-04-09

Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)

Phase 2 Completed

32 enrolled 21 charts

Plasma cell

Multiple Myeloma

NCT01083602 2017-12-21

MACS1271

Phase 2 Completed

55 enrolled 11 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT01460940 2017-11-14

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2 Completed

24 enrolled 7 charts

Lymphoid

Hodgkin Disease

NCT00880269 2017-02-23

Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

Phase 2 Completed

59 enrolled 7 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT00777049 2016-07-15

Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer

Phase 2 Completed

54 enrolled 12 charts

Breast

Breast Neoplasms

NCT00901147 2014-06-27

Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Phase 2 Completed

25 enrolled

Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT01136499 2013-03-06